Abstract: A control method and apparatus for displaying multimedia content, an electronic device, and a medium. The method includes: displaying a first-type multimedia content on a first content display layer of a first-type multimedia content display interface, the first-type multimedia content display interface including: a first user interaction layer and the first content display layer, the first user interaction layer being superimposed and displayed on the first content display layer; and receiving a first swiping operation inputted by a user on the user interaction layer, and exiting the first-type multimedia content display interface. That is, a swiping operation triggers to exit the first-type multimedia content display interface, as the swiping operation is significantly different from a click operation, the user is provided with a multimedia content display control method that is more consistent with the user's operation habit, improving the user experience.

Abstract: The present invention provides a cochlear outer hair cell (OHC) regenerated by ectopic joint overexpression of Atoh1 and Ikzf2 and an application thereof. Specifically, the present invention provides an active ingredient combination capable of being used for regenerating a cochlear OHC, and a use thereof. The active ingredient combination comprises an Ikzf2 protein and an Atoh1 protein; and after the active ingredient combination is administered to a subject suffering from hearing impairment related to cochlear OHC degeneration and/or injury, hearing impairment can be alleviated by regenerating an OHC-like cell. A new method is provided for clinical treatment of hearing impairment.

Abstract: Provided are an interaction method and apparatus, an electronic device, and a storage medium. The method includes displaying a target page, where target content containing a target object is displayed in the target page; receiving a shake trigger operation of a user; and in response to the shake trigger operation, displaying associated content of the target content in a layer above the target page and displaying the detail page of the target object after completing displaying the associated content.

Abstract: Peptides (and derivatives thereof), topical compositions, and methods of diminishing signs of aging and/or improving health of human integuments are provided. The peptides are derived from human Growth Differentiation Factor 11 (GDF-11) and typically have one or more chemical modifications of the amino acid residues. Preferred modifications of GDF-11 fragments include methionine oxidation.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: These compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: These compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.

Abstract: The disclosure discloses an anti-flatulence milk bottle, which comprises a bottle body and a nipple, wherein an edge of the nipple is arranged at a bottleneck of the bottle body through a threaded cover, the threaded cover is in threaded connection with a periphery of the bottleneck, a first air returning cover and a second air returning cover are arranged between the nipple and the bottleneck, a first gap is formed between the first air returning cover and the second air returning cover, a second gap is formed between the threaded cover and an outer surface of the bottleneck, the first gap is communicated with the second gap, the first air returning cover is provided with a first opening communicated with an interior of the bottle body, and the first gap, the second gap and the first opening form a confluence passage.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: The disclosure discloses an anti-flatulence milk bottle, which comprises a bottle body and a nipple, wherein an edge of the nipple is arranged at a bottleneck of the bottle body through a threaded cover, the threaded cover is in threaded connection with a periphery of the bottleneck, a first air returning cover and a second air returning cover are arranged between the nipple and the bottleneck, a first gap is formed between the first air returning cover and the second air returning cover, a second gap is formed between the threaded cover and an outer surface of the bottleneck, the first gap is communicated with the second gap, the first air returning cover is provided with a first opening communicated with an interior of the bottle body, and the first gap, the second gap and the first opening form a confluence passage.

Abstract: A control circuit (115), a control method, a DC-DC converter and an electronic device are provided. The control circuit (115) is used to control the DC-DC converter to switch its operation modes. In the control circuit (115), whether mode of the DC-DC converter is to be switched is judged according to parameters of a first duration of an active duration and a second duration of an inactive duration. Comparison of analog values is prevented, and as a result, the use of the analog comparator is reduced, thus the influence of the semiconductor processes on designing a controller can be reduced.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.

Abstract: The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as TNF-?, IL-1?, IL-6, MMP-1 and MMP-3.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as TNF-?, IL-1?, IL-6, MMP-1 and MMP-3.

Abstract: The present invention provides edible compositions comprising a sweet taste modulator of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste in a food product.